Bristol-Myers Squibb Will Localize The Production Of Antitumor Dasatinib In Russia
Bristol-Myers Squibb and the group of "R-Pharm" companies signed a license agreement regarding the localization of production anticancer drug dasatinib (trade name Spraysel) in Russia.
Dasatinib is a drug for the treatment of adult patients with chronic myeloid leukemia that was registered in Russia in 2008.
Last autumn, it became known about the localization of another drug by Bristol-Myers Squibb, an antiretroviral drug atazanavir on Yaroslavl factlory "R-Pharm". According to Bristol-Myers Squibb CEO in Russia Soren Giza, agreement on the localization of dasatinib and atazanavir is the result of the systematic development of cooperation with the "R-Pharm" in a socially important segment of the Russian health care.
In turn, the head director of the group of "R-Pharm" companies Vassily Ignatiev said that the efforts of both producers contribute to increasing the availability of highly innovative products for Russian patients.
- AbbVie Can Abandon The Acquisition Of Shire
- Antineoplastic Drug by Bristol-Myers Squibb Successfully Passed Phase II Clinical Trials
- Bristol-Myers Squibb announced the acquisition Flexus for $ 1.25 billion